Alvotech is looking for new partnerships where it can offer biologics manufacturing capabilities cooperation in the commercialization of its own developed biosimilar pipeline. Its state of the art manufacturing capabilities, freedom to operate for early launches, contract manufacturing capabilities for biologics, and in-house clinical capabilities are just a few of the many reasons why Alvotech is the partner of excellence for biosimilar initiatives.
Alvotech is a global biopharmaceutical company dedicated to becoming one of the leaders in the biosimilar monoclonal antibody market. The company has six key biosimilar molecules in development and a new state-of-the-art manufacturing plant for development and commercial supply.
We are focused on delivering value to our customers around the world as we increase the accessibility and affordability of new high quality biopharmaceuticals.
For the second year in a row, Alvogen stood out in the crowd at the annual CPhI event in October, which this year was hosted in Paris, France. CPhI is the premiere event of the year in the pharma industry calendar and the largest networking event in the world, attracting more than 30,000 visitors from over 140 countries.
Alvotech’s management team is building a leading biopharmaceutical company. Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. Robert Wessman is the Chairman and founder of Alvotech and the leadership team is helmed by Dr. Andreas Herrmann.